National Institutes of Health: Glioblastoma trials
The registry lists 127 Glioblastoma studies with National Institutes of Health as lead sponsor. 7 are open to participants now and 58 have results posted.
Phase 1 68Phase 2 73Phase 3 3No phase 10(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
- Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
- Comparison of TransMID vs Standard Treatment of Cancerous Brain TumorsCompletedNCT00088400Phase 3
- Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma MultiformeTerminatedNCT00075491Phase 2
- Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCompletedNCT00070525Phase 2
- Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
- Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00058097Phase 2
- FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
- Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00053183Phase 1
- Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
- Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
- Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00049387Phase 1
- Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT00045565Phase 1
- Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
- Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the BrainCompletedNCT00032097Phase 1
- Genetic Analysis of Brain TumorsTerminatedNCT00031538
- Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
- Efficacy of Distant Healing in Glioblastoma TreatmentCompletedNCT00029783Phase 2
- Radiation Therapy in Treating Patients With GlioblastomaCompletedNCT00019058Phase 1
- CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00016328Phase 2
- Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00014170Phase 2
- Natural History of Patients With Brain and Spinal Cord TumorsCompletedNCT00009035
- Bortezomib in Treating Patients With Recurrent GliomaTerminatedNCT00006773Phase 1
- Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00005856Phase 1/2
- Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma MultiformeCompletedNCT00004262Phase 1
- Evaluation of Factors in Human Brain TumorsCompletedNCT00001171
- Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the TumorCompletedNCT00001148